These genetic modifications make VPM1002 a beneficial vaccine for comorbid TB-HIV through enhancing antigen presentation and CD8+ and AIM2 inflammasome activation using LLO and inducing further IFN-γ production, which is especially beneficial for the immunocompromised [48]. The gene discussed is CD8A; the disease is tuberculosis.